Association of Growth Hormone Adherence and Growth Outcomes in Paediatric Patients: Results From a Clinical Registry.

IF 2.4 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Clinical Endocrinology Pub Date : 2026-06-01 Epub Date: 2026-02-12 DOI:10.1111/cen.70105

Tilman Robert Rohrer, Klaus Hartmann, Peter Herbert Kann, Tobias Vogelmann, Dorna Hogeabri, Tino Schubert

{"title":"Association of Growth Hormone Adherence and Growth Outcomes in Paediatric Patients: Results From a Clinical Registry.","authors":"Tilman Robert Rohrer, Klaus Hartmann, Peter Herbert Kann, Tobias Vogelmann, Dorna Hogeabri, Tino Schubert","doi":"10.1111/cen.70105","DOIUrl":null,"url":null,"abstract":"Objective: Daily growth hormone (GH) therapy for growth disorders requires long-term adherence. The aim of this study was to investigate the association of adherence with 2-year growth outcomes in paediatric patients receiving daily GH therapy in a clinical registry.Design: Retrospective cohort study.Patients: Patients with growth disorder were categorized after 2 years of treatment into low adherence (< 85%), high adherence (85%-110%) and adherence > 110% groups. Only patients with consistent adherence classification across both years were included in the 2-year outcome analysis.Measurements: Growth outcomes were compared the change in height standard deviation score (ΔHSDS) over 2 years. Statistical tests were performed using the nonparametric Spearman's rank correlation coefficient and a general linear regression model.Results: Seventy-four patients were analysed after 2 years of treatment. Mean ΔHSDS was 0.87 in the high adherence group and 0.33 in the low adherence group (absolute difference 0.54). Using the Spearman's correlation coefficient, ΔHSDS was statistically significantly positively correlated with high adherence compared to low adherence (rs = 0.33; p < 0.01). The linear regression results support these findings and estimate an improved ΔHSDS of 0.44 for patients in the high adherence group compared to the low adherence group (p = 0.03). Mean ΔHSDS in the adherence > 110% group was 0.79.Conclusion: Sustained high adherence (≥ 85%) to daily GH therapy was associated with clinically meaningful improvement in growth over 2 years.","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":"603-611"},"PeriodicalIF":2.4000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13124680/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/cen.70105","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Daily growth hormone (GH) therapy for growth disorders requires long-term adherence. The aim of this study was to investigate the association of adherence with 2-year growth outcomes in paediatric patients receiving daily GH therapy in a clinical registry.

Design: Retrospective cohort study.

Patients: Patients with growth disorder were categorized after 2 years of treatment into low adherence (< 85%), high adherence (85%-110%) and adherence > 110% groups. Only patients with consistent adherence classification across both years were included in the 2-year outcome analysis.

Measurements: Growth outcomes were compared the change in height standard deviation score (ΔHSDS) over 2 years. Statistical tests were performed using the nonparametric Spearman's rank correlation coefficient and a general linear regression model.

Results: Seventy-four patients were analysed after 2 years of treatment. Mean ΔHSDS was 0.87 in the high adherence group and 0.33 in the low adherence group (absolute difference 0.54). Using the Spearman's correlation coefficient, ΔHSDS was statistically significantly positively correlated with high adherence compared to low adherence (rs = 0.33; p < 0.01). The linear regression results support these findings and estimate an improved ΔHSDS of 0.44 for patients in the high adherence group compared to the low adherence group (p = 0.03). Mean ΔHSDS in the adherence > 110% group was 0.79.

Conclusion: Sustained high adherence (≥ 85%) to daily GH therapy was associated with clinically meaningful improvement in growth over 2 years.

查看原文本刊更多论文

生长激素依从性与儿科患者生长结局的关系：来自临床登记的结果。

目的：每日生长激素（GH）治疗生长障碍需要长期坚持。本研究的目的是调查临床登记中接受每日生长激素治疗的儿科患者的依从性与2年生长结果的关系。设计：回顾性队列研究。患者：生长障碍患者在治疗2年后被分为低依从性组（110%）。只有两年内依从性分类一致的患者才被纳入2年结果分析。测量方法：比较两年内身高标准差评分（ΔHSDS）的变化。采用非参数Spearman等级相关系数和一般线性回归模型进行统计检验。结果：74例患者经过2年的治疗。高依从性组的平均ΔHSDS为0.87，低依从性组的平均ΔHSDS为0.33（绝对差为0.54）。使用Spearman相关系数，ΔHSDS与高依从性与低依从性呈正相关（rs = 0.33; p = 110%组为0.79）。结论：持续高依从性（≥85%）每日生长激素治疗与2年内临床有意义的生长改善相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Endocrinology 医学-内分泌学与代谢

CiteScore

6.40

自引率

3.10%

发文量

192

审稿时长

1 months

期刊介绍： Clinical Endocrinology publishes papers and reviews which focus on the clinical aspects of endocrinology, including the clinical application of molecular endocrinology. It does not publish papers relating directly to diabetes care and clinical management. It features reviews, original papers, commentaries, correspondence and Clinical Questions. Clinical Endocrinology is essential reading not only for those engaged in endocrinological research but also for those involved primarily in clinical practice.